期刊
JOURNAL OF INFECTIOUS DISEASES
卷 220, 期 6, 页码 990-1000出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiz225
关键词
Herpes simplex; HSV2; vaccine; genital herpes
资金
- Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID)
- NIAID
- Sanofi Pasteur
- National Cancer Institute, National Institutes of Health [HHSN261200800001E]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000548] Funding Source: NIH RePORTER
Background. Herpes simplex virus 2 (HSV2) causes genital herpes in >400 million persons worldwide. Methods. We conducted a randomized, double-blinded, placebo-controlled trial of a replication-defective HSV2 vaccine, HSV529. Twenty adults were enrolled in each of 3 serogroups of individuals: those negative for both HSV1 and HSV2 (HSV1(-)/HSV2(-)), those positive or negative for HSV1 and positive for HSV2 (HSV1(+/-)/HSV2(+)), and those positive for HSV1 and negative for HSV2 (HSV1(+)/HSV2(-)). Sixty participants received vaccine or placebo at 0, 1, and 6 months. The primary end point was the frequency of solicited local and systemic reactions to vaccination. Results. Eighty-nine percent of vaccinees experienced mild-to-moderate solicited injection site reactions, compared with 47% of placebo recipients (95% confidence interval [CI], 12.9%-67.6%; P = .006). Sixty-four percent of vaccinees experienced systemic reactions, compared with 53% of placebo recipients (95% CI, -17.9% to 40.2%; P = .44). Seventy-eight percent of HSV1(-)/HSV2(-) vaccine recipients had a >= 4-fold increase in neutralizing antibody titer after 3 doses of vaccine, whereas none of the participants in the other serogroups had such responses. HSV2-specific CD4(+) T-cell responses were detected in 36%, 46%, and 27% of HSV1(-)/HSV2(-), HSV1(+/-)/HSV2(+), and HSV1(+)/HSV2(-) participants, respectively, 1 month after the third dose of vaccine, and CD8(+) T-cell responses were detected in 14%, 8%, and 18% of participants, respectively. Conclusions. HSV529 vaccine was safe and elicited neutralizing antibody and modest CD4(+) T-cell responses in HSV-seronegative vaccinees.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据